Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.68 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.54 |
| ▸ | TK1 | P04183 | 4/20 | 0.49 |
| ▸ | TK2 | O00142 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA5A | P35218 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9326675 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL10664373 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL9324478 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL21886791 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL30976654 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL22992340 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL13273339 | 0.91 | RNASE1 (0.82) | RNASE1TK1TK2ABCG2ABCB1 | |
| SCHEMBL7071383 | 0.90 | RNASE1 (0.55) | RNASE1UPP1TK1TK2 | |
| SCHEMBL6237573 | 0.90 | RNASE1 (0.55) | RNASE1UPP1TK1TK2 | |
| SCHEMBL20833584 | 0.89 | UPP1 (0.54) | RNASE1UPP1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1186612-B1 | PROCESS FOR THE PREPARATION OF CYTIDINE DERIVATIVES | MITSUI CHEMICALS INC (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-6822090-B2 | GENERATION OF PREFERENTIAL URIDINE DERIVATIVE; OBTAIN REACTION MIXTURE, EXPOSE TO TERTIARY AMINE, DEHYDRATING REACTANT AND AMMONIA, RECOVER CYTIDINE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20030032797-A1 | Process for the preparation of cytidine derivatives | MITSUI CHEMICALS, INC. (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1186612-A1 | PROCESS FOR THE PREPARATION OF CYTIDINE DERIVATIVES | Mitsui Chemicals, Inc. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032797-A1 | Process for the preparation of cytidine derivatives | CDA, DCTD, APOBEC3A | RNASE1 465/4885UPP1 68/4885TK1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.